Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.58 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677899 | 0.86 | F10 (0.60) | F10PTGS2 | |
| SCHEMBL118847 | 0.85 | F10 (0.60) | F10PTGS2 | |
| SCHEMBL15200539 | 0.84 | F10 (0.56) | F10PTGS2 | |
| SCHEMBL25207144 | 0.84 | GAA (0.56) | F10PTGS2 | |
| SCHEMBL19647445 | 0.83 | F10 (0.62) | F10PTGS2 | |
| SCHEMBL19647435 | 0.83 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL28407706 | 0.83 | F10 (0.59) | F10PTGS2 | |
| SCHEMBL1679321 | 0.83 | F10 (0.65) | F10PTGS2 | |
| SCHEMBL15203305 | 0.82 | F10 (0.54) | F10PTGS2 | |
| SCHEMBL15195101 | 0.82 | F10 (0.53) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3168220-B1 | NOVEL METHOD FOR SYNTHESIZING RIVAROXABAN INTERMEDIATE, 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL}MORPHOLIN-3-ONE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2019-03-13 | — | — | EP | disclosed |
| EP-3168220-A1 | NOVEL METHOD FOR SYNTHESIZING RIVAROXABAN INTERMEDIATE, 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL}MORPHOLIN-3-ONE | Zhejiang Huahai Pharmaceutical Co., Ltd. (CN) | 2017-05-17 | — | — | EP | disclosed |
| EP-2722330-B1 | NOVEL METHOD FOR SYNTHESIZING RIVAROXABAN INTERMEDIATE, 4-{4-[(5S)-5-(AMINOMETHYL)-2-OXO-1,3-OXAZOLIDIN-3-YL]PHENYL}MORPHOLIN-3-ONE | ZHEJIANG HUAHAI PHARM CO LTD (CN) | 2017-04-26 | — | — | EP | disclosed |
| US-9598403-B2 | Process for the preparation of rivaroxaban | AMNEAL PHARMACEUTICALS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598403-B2 | Process for the preparation of rivaroxaban | AMNEAL PHARMACEUTICALS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2837628-B1 | METHOD FOR PREPARING RIVAROXABAN INTERMEDIATE | CHINA NAT MEDICINES GUORUI PHARMACEUTICAL CO LTD (CN) | 2016-11-30 | — | — | EP | disclosed |
| US-20160194309-A1 | A Process For The Preparation Of Rivaroxaban | AMNEAL PHARMACEUTICALS LLC | 2016-07-07 | — | — | US | disclosed |
| US-20160194309-A1 | A Process For The Preparation Of Rivaroxaban | AMNEAL PHARMACEUTICALS LLC | 2016-07-07 | — | — | US | disclosed |
| EP-2424847-B1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC (CA) | 2016-04-06 | — | — | EP | disclosed |
| US-9126990-B2 | Method for synthesizing rivaroxaban intermediate, 4-(4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazoligdin-3-YL]phenyl)morpholin-3-one | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD (CN) | 2015-09-08 | — | — | US | disclosed |
| WO-2010124385-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194309-A1 | A Process For The Preparation Of Rivaroxaban | TFPI, VKORC1, VKORC1L1 | F10 13/4885MTOR 2946/4885PTGS2 1693/4885 |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 8/4885MTOR 1369/4885PTGS2 1741/4885 |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 7/4885MTOR 1362/4885PTGS2 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.